NKTR - Nektar Therapeutics
| Previous Close | 33.89 |
| Open | 34.06 |
| Bid | 34.57 x 800 |
| Ask | 34.61 x 800 |
| Day's Range | 33.61 - 35.55 |
| 52 Week Range | 29.22 - 69.76 |
| Volume | 1,223,536 |
| Avg. Volume | 1,551,439 |
| Market Cap | 6.035B |
| Beta (3Y Monthly) | 3.19 |
| PE Ratio (TTM) | 9.65 |
| EPS (TTM) | 3.59 |
| Earnings Date | Aug 6, 2019 - Aug 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 69.91 |
- Insider Monkey•3 days ago
Is Nektar Therapeutics (NKTR) A Good Stock To Buy?
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 20 S&P 500 […]
- MoneyShow•5 days ago
Nektar's Drug Could be a "Big Deal"
Nektar (NKTR) has a drug called NKTR-358 and they presented data from a clinical trial at EULAR (European League Against Rheumatism); in short NKTR-358 could be a very big deal, explains small cap expert Tom Bishop, editor of BI Research.
- MarketWatch•7 days ago
Harry Boxer’s three biotech stocks on the move include Nektar Therapeutics
Three biotechnology companies, along with recent IPO Pinterest, are among our four charts to watch today. G1 Therapeutics Inc. (GTHX) jumped $4.75, or 24%, to $24.50 on 2.2 million shares traded Tuesday. The move, on over five times its average volume, came on news of encouraging data from the company’s Phase II study of its trilaciclib treatment for metastatic triple-negative breast cancer.
- Markit•8 days ago
See what the IHS Markit Score report has to say about Nektar Therapeutics.
Nektar Therapeutics NASDAQ/NGS:NKTRView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for NKTR with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on June 14. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding NKTR are favorable, with net inflows of $8.09 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Simply Wall St.•12 days ago
Should We Be Delighted With Nektar Therapeutics's (NASDAQ:NKTR) ROE Of 40%?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
- InvestorPlace•12 days ago
3 Big Stock Charts for Friday: Symantec, Vertex Pharmaceuticals and Nektar Therapeutics
It was a victory for stocks on Thursday, though not a decisive one. The 0.41% gain logged by the S&P 500 keeps it above some important technical support, but one rough day could still put the broad market into something of a tailspin.Walt Disney (NYSE:DIS) shares did more than their fair share of the heavy lifting, up 4.4% largely after Morgan Stanley predicted its planned streaming product, Disney+, would be even more successful than most investors have given it credit for. Restoration Hardware Holdings (NYSE:RH), also just called RH, logged one of the biggest wins on Thursday though, rallying more than 15% after topping its fiscal first quarter estimates.At the other end of the spectrum, Twitter (NYSE:TWTR) fell 3.1% after MoffettNathanson analyst Michael Nathanson suggested the recent strength made it a good time to take some profits.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNone make for great trading options headed into the weekend though. Rather, it's the stock charts of Nektar Therapeutics (NASDAQ:NKTR), Vertex Pharmaceuticals (NASDAQ:VRTX) and Symantec (NASDAQ:SYMC) that present themselves as the top prospects. Here's why. Vertex Pharmaceuticals (VRTX)Vertex Pharmaceuticals is no stranger to big swings in both directions. In fact, big swings are the norm. These aren't just sizeable, trade-worthy movements though. They're actually pretty predictable in terms of size and scope. The turns are taking shape pretty much where they should, even if VRTX is incapable of moving anywhere in a straight line. * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 The stock's back at a well-established technical floor now, suggesting a rebound move is nigh. This revisit of a familiar floor does look a little bit different though, in that the stock's struggled to push up and off of it. It may be a clue that the bears are just waiting to deal a proverbial death blow. Click to Enlarge • The range in question is plotted with white lines on both stock charts, tracing the major highs and lows going all the way back to 2017.• Bolstering the case for a bounce here is the fact that the stochastic indicator is into oversold territory. That's not a condition that's been allowed to last long for Vertex Pharmaceuticals, but…• …zooming out shows that VRTX has been hugging the floor in question since April. It should have rebounded by now. One or two rough days could break the support, perhaps unleashing a wave of pent-up selling. Nektar Therapeutics (NKTR)Nektar Therapeutics was beaten so badly last year that traders have been wary of stepping back into it now. But, to its credit, at least the bleeding has stopped. The few bulls still testing the waters have even established a technical floor since late last year.There's a much bigger method to the madness though. That is, the selling has been slowly but surely ground to a halt, and the would-be buyers are establishing a base from which to carry the stock higher again. While there's still much work to be done, that work is being done. Click to Enlarge • The floor in question is plotted in yellow on both stock charts, tagging all the key lows going back to late December.• Zooming out to the weekly chart we can see shares of NKTR have already started to poke through falling resistance lines.• The key to, and signal of, a fully established breakout thrust is the next move above the white 200-day moving average line at $40.86 and the weekly chart's Chaikin line moving back above the zero level. Symantec (SYMC)In late March Symantec was featured as a name that had been range-bound for several weeks, and of the effort to push above a well-established ceiling at the time failed, a retreat back to the lower boundary of that range was likely.SYMC did indeed punch through that ceiling, though it was a flawed break. With a gap left in the rearview mirror, shares started to peel back in May and eventually made their way back to the support portion of the range anyway. Since kissing that floor late last month though, the bulls appear to have regrouped and are ready to make the trip back to the ceiling again. Click to Enlarge • The range in question is between $17.50 and $23.60, marked with red and yellow lines on both stock charts.• The weekly chart also shows an oversold stochastic indicator, which more often than not does point where Symantec has moved to an unsustainable extreme.• Curiously, though shares have yet to make a solid upward move, the weekly chart's rising Chaikin line suggests there's a lot more buying interest than selling pressure in place right now.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 * 7 Value Stocks That Are Flying Under the Radar * 6 Mouth-Watering Fast Food Stocks for Growth Investors Compare Brokers The post 3 Big Stock Charts for Friday: Symantec, Vertex Pharmaceuticals and Nektar Therapeutics appeared first on InvestorPlace.
- Benzinga•13 days ago
The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 12) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp ...
- PR Newswire•13 days ago
First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology
MADRID and SAN FRANCISCO, June 13, 2019 /PRNewswire/ -- Nektar Therapeutics (NKTR) today announced the results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator in clinical development for the treatment of autoimmune and other chronic inflammatory conditions. The data, which were presented during an oral session at the Annual European Congress of Rheumatology (EULAR 2019) in Madrid, show that NKTR-358 was safe and well-tolerated and led to a marked and selective dose-dependent expansion of T regulatory cells with no measurable effect on conventional CD4+ and CD8+ T cells (Tcons). NKTR-358 was discovered by Nektar and is being co-developed and commercialized in partnership with Eli Lilly and Company.
- Thomson Reuters StreetEvents•15 days ago
Edited Transcript of NKTR earnings conference call or presentation 8-May-19 9:00pm GMT
Q1 2019 Nektar Therapeutics Earnings Call
- PR Newswire•15 days ago
Nektar Therapeutics to Host Webcast Conference Call with Immunology Expert for Analysts & Investors During 2019 European Congress of Rheumatology (EULAR 2019)
SAN FRANCISCO , June 11, 2019 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will webcast an analyst and investor conference call with an immunology expert and company management ...
- Zacks•15 days ago
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
Smart Beta ETF report for EUSA
- Benzinga•18 days ago
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Biotech stocks staged a steady recovery last week. ASCO presentations dominated the headlines, with Iovance Biotherapeutics Inc (NASDAQ: IOVA ) and Mirati Therapeutics Inc (NASDAQ: MRTX ) among the biggest ...
- Zacks•19 days ago
Nektar (NKTR) Down 7% Since Last Earnings Report: Can It Rebound?
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks•21 days ago
Cancer-Fighting Stocks & ETF: What You Need to Know
Many biotech stocks soared after they presented very promising cancer treatment results at the ASCO conference
- Zacks•22 days ago
Nektar (NKTR) in Focus: Stock Moves 8.8% Higher
Nektar (NKTR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
- Motley Fool•23 days ago
Why El Paso Electric, Nektar Therapeutics, and Hecla Mining Jumped Today
Factors including acquisition activity, safe-haven buying, and favorable corporate news boosted these stocks.
- Investor's Business Daily•23 days ago
Who Are The Winners And Losers From The Year's Biggest Cancer Meeting?
Biotech stocks jumped Monday with Nektar Therapeutics, Iovance Therapeutics and Seattle Genetics stocks among the market leaders. All three rose on promising studies in cancer treatment.
- Zacks•23 days ago
Why Cancer-Fighting Stocks & ETFs Are Soaring
The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
- TheStreet.com•23 days ago
Nektar Therapeutics Jumps on Positive Results From Melanoma Treatment Study
were up 10.2% to $34.50 Monday after the company reported positive results from the clinical study of its melanoma treatment candidates. The Chicago-based company said that its two candidates, bempegaldesleukin and nivolumab, were showing positive signs in testing. The Stage IV melanoma patients enrolled in the ongoing PIVOT-02 study continue to experience both deepening and durability of response over time," said Jonathan Zalevsky, chief scientific officer at Nektar Therapeutics.
- PR Newswire•25 days ago
Nektar Therapeutics Presents Biomarker and Clinical Data from PIVOT-02 Phase 2 Study of Bempegaldesleukin with Nivolumab at 2019 ASCO Annual Meeting
CHICAGO , June 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that biomarker and clinical data from PIVOT-02 is being presented at the 2019 American Society of Clinical Oncology ...
- ETF.com•26 days ago
How To Know What’s In Your ETF
Our free tools and resources can help with your due diligence efforts.
- MarketWatch•26 days ago
These 6 stocks in the S&P 500 are down at least 50% — and analysts say buy
Overall, 14 stocks among the S&P 500 are down at least 50% from their 52-week highs. Are there bargains among them?
- Motley Fool•last month
What Is Nektar Therapeutics' New Game Plan?
Investors want to know what's behind the company's plan to split itself in two.
- Zacks•last month
Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary
Nektar (NKTR) forms wholly-owned subsidiary, Inheris Biopharm, focusing on CNS pipeline. The subsidiary will mainly be responsible for potential commercialization of under review pain drug, NKTR-181.
- American City Business Journals•last month
Why this pain-killing opioid is spinning into a new company
Nektar's wholly owned subsidiary might relieve some pain if NKTR-181 finds it tough to win a recommendation in August from an FDA advisory committee yet also provide financial upside if its unique opioid is approved.
